Experts Hail Wegovy Approval as 'Win-Win' for Patients and Major Obesity Battle Turning Point
In a landmark decision, the weight loss drug Wegovy has received approval for prescription not only for weight management but also to help reduce the risk of major cardiovascular events such as heart attacks and strokes. This move by the National Institute for Health and Care Excellence (Nice) has been celebrated by medical experts as a significant advancement in the fight against obesity and related health conditions.
A Dual-Purpose Treatment Breakthrough
The green light from Nice allows semaglutide, marketed as Wegovy, to be prescribed to overweight and obese patients who also live with specific heart and circulatory conditions. This dual-purpose approval marks a pivotal shift in treatment approaches, addressing both weight and cardiovascular risk simultaneously.
Professor Naveed Sattar, an expert in cardiometabolic medicine at the University of Glasgow, emphasized the transformative potential of this development. "We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease but also lead to meaningful weight loss," he stated. "These treatments improve patients' quality of life in a meaningful way, making this a genuine win-win."
Professor Sattar further highlighted that with many cardiovascular disease patients struggling with excess weight, focusing solely on traditional risk factors like lipids and blood pressure is no longer sufficient. Directly addressing weight is crucial for optimal patient outcomes, and this new guidance enables precisely that strategy.
Cautionary Notes on Implementation and Side Effects
While the announcement has been met with widespread enthusiasm, experts have issued important cautions regarding the drug's rollout and potential side effects. GLP-1 receptor agonist drugs, including semaglutide, can reduce muscle mass along with fat, necessitating complementary physical activity such as resistance training.
Professor Robert Storey of the University of Sheffield pointed out that this requirement may not be feasible for frail patients, underscoring the need for careful targeting of prescriptions. "The benefits need to be balanced against the risk of side effects," he advised, adding that proper training for injection, ongoing monitoring, and adequate NHS resources are essential to realize the full benefits of the Nice guidance.
Addressing Health Inequalities and System Capacity
A critical concern raised by academics is the potential for a postcode lottery in care as the drugs are rolled out this summer. They have urged local health bodies and integrated care boards (ICBs) to ensure equitable access to prevent exacerbating existing health inequalities.
Professor Riyaz Patel from UCL referenced previous issues with variable delivery of beneficial drugs like inclisiran for cholesterol lowering, warning that similar disparities must be avoided with semaglutide. "ICBs must ensure this does not happen with this Nice technology appraisal, else we risk exacerbating health inequalities," he asserted, noting that this treatment should instead serve as a powerful tool to reduce such disparities.
The Role of Physical Activity and Holistic Support
Huw Edwards, chief executive of ukactive, welcomed the measure as a significant step forward in tackling obesity and reducing cardiovascular disease risk. However, he stressed that medications like semaglutide are not a standalone solution. "Evidence shows that without physical activity, particularly strength training, patients risk losing muscle mass, which can undermine long-term health outcomes," Edwards explained.
To ensure sustainable results, he advocated for combining drug treatment with structured physical activity and broader lifestyle support, emphasizing a holistic approach to health improvement.
A New Era in Obesity and Cardiovascular Care
Overall, the approval of Wegovy for both weight loss and cardiovascular risk reduction represents an exciting development for patients and healthcare providers alike. It provides another powerful tool in the arsenal against cardiovascular disease while addressing the complex interplay between obesity and heart health.
As the NHS prepares for the summer rollout, the focus will be on implementing this guidance effectively, balancing benefits with risks, and ensuring that all patients have fair access to this promising treatment option.
